Provention Bio Equity 2025

Provention Bio Aktienanalyse

What does Provention Bio do?

Provention Bio Inc is a US biotechnology company specializing in the development of preventive therapies for autoimmune diseases and other chronic conditions. The company was founded in 2016 by a group of experienced biotech managers and has its headquarters in Oldwick, New Jersey. The history of Provention Bio begins with the recognition that many current treatments for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus only aim to treat the symptoms of the disease rather than addressing their causes. Therefore, the company is committed to developing innovative and preventive therapies that directly target the causes of autoimmune diseases. Provention Bio's business model is based on sourcing and developing new therapies through to commercialization. The company is dedicated to early-stage research and development and works closely with academic institutions, government agencies, and other companies to achieve its goals. Additionally, Provention Bio invests in clinical trials to prove the efficacy of its therapies and ensure their approval by regulatory authorities. The various divisions of Provention Bio encompass some of the most important autoimmune diseases currently lacking effective cures. These include type 1 diabetes, celiac disease, lupus, MS, and other rare autoinflammatory diseases. Provention Bio's products aim to regulate the immune system and enhance the body's self-healing by influencing biological processes. One of Provention Bio's key products is Teplizumab, a preventive medication for the treatment of type 1 diabetes. The company has acquired the exclusive global rights to this medication, relying on promising results from its clinical trials. Since its FDA approval in 2021, the medication has filled an important market need. Additionally, Provention Bio has several other potential therapies in its pipeline. Among them is PRV-3279, a medication specifically developed for the treatment of celiac disease, currently in phase 2 clinical trials. Additionally, Teplizumab is being investigated for use in other autoimmune diseases such as lupus and MS. The goal of Provention Bio is to positively impact the quality of life and health of millions of people worldwide. The company is working hard to develop innovative preventive therapy approaches that focus on the causes of autoimmune diseases rather than just treating the symptoms. In doing so, Provention Bio is a significant addition to the wide range of existing treatment options by significantly expanding therapeutic choices. In summary, Provention Bio Inc is considered an emerging biotechnology company with great potential in the preventive treatment of autoimmune diseases. The company has a promising pipeline of therapies that have the potential to improve the lives of millions of people worldwide. The company aims to develop preventive and effective therapies that directly address the causes of autoimmune diseases. Provention Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Provention Bio's Equity

Provention Bio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Provention Bio's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Provention Bio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Provention Bio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Provention Bio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Provention Bio stock

What is the equity of Provention Bio this year?

Provention Bio has equity of 121.85 M USD this year.

What was the equity of Provention Bio compared to the previous year?

The equity of Provention Bio has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Provention Bio?

A high equity is advantageous for investors of Provention Bio as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Provention Bio?

A low equity can be a risk for investors of Provention Bio, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Provention Bio affect the company?

An increase in equity of Provention Bio can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Provention Bio affect the company?

A reduction in equity of Provention Bio can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Provention Bio?

Some factors that can affect the equity of Provention Bio include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Provention Bio so important for investors?

The equity of Provention Bio is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Provention Bio take to change the equity?

To change equity, Provention Bio can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Provention Bio pay?

Over the past 12 months, Provention Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Provention Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Provention Bio?

The current dividend yield of Provention Bio is .

When does Provention Bio pay dividends?

Provention Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Provention Bio?

Provention Bio paid dividends every year for the past 0 years.

What is the dividend of Provention Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Provention Bio located?

Provention Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Provention Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Provention Bio from 10/8/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2025.

When did Provention Bio pay the last dividend?

The last dividend was paid out on 10/8/2025.

What was the dividend of Provention Bio in the year 2024?

In the year 2024, Provention Bio distributed 0 USD as dividends.

In which currency does Provention Bio pay out the dividend?

The dividends of Provention Bio are distributed in USD.